A Phase I Clinical Study of IX001 TCR-T Injection in the Treatment of Advanced Pancreatic Cancer Patients With KRAS G12V Mutation

• Status: RECRUITING
• Trial end date: 2027-09-27

Summary

This is a single-arm, open-label clinical study to evaluate the safety, tolerability and preliminary efficacy of IX001 TCR-T injection in advanced pancreatic cancer patients with KRAS G12V mutation.

• Phase: PHASE1

Details

• Lead Sponsor: Sun Yat-sen University
• Collaborator: ImmuXell Biotech Ltd.
• Treatments: Cyclophosphamide; fludarabine; fludarabine phosphate